You are here: Industry Insights > AstraZeneca

News List

AstraZeneca says COVID-19 vaccine 76 per cent effective in new analysis, to seek US approval expresspharma
March 26, 2021
The European Union’s drug regulator said last week the vaccine was clearly safe, but Europeans remain skeptical about its safety.
NIAID statement on AstraZeneca vaccine and AstraZeneca update worldpharmanews
March 24, 2021
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.
US health agency questions AstraZeneca’s Covid-19 vaccine trial data pharmaceutical-technology
March 24, 2021
US health officials have questioned the validity of AstraZeneca’s most recent vaccine trial results, saying the data provided by the company may be “outdated”.
Oxford AstraZeneca jabs effective against severe COVID new trial in US confirms expresspharma
March 24, 2021
Oxford University said that the absolute efficacy of the jabs is higher in the new study than observed in the Oxford-led studies.
New data boosts AstraZeneca COVID-19 vaccine in US expresspharma
March 23, 2021
The trials in the US, Chile and Peru showed the vaccine was 79 per cent effective at preventing symptomatic COVID-19.
South Africa sells COVID-19 vaccines procured from AstraZeneca to other AU member states expresspharma
March 23, 2021
The country had paused AstraZeneca vaccinations last month because of a small trial showing the shot offered minimal protection against mild to moderate illness caused by the dominant local coronavirus variant.
KM Biologics commences clinical trial of COVID-19 vaccine candidate expresspharma
March 23, 2021
The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune response.
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment worldpharmanews
March 22, 2021
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
WHO statement on AstraZeneca COVID-19 vaccine safety signals worldpharmanews
March 22, 2021
Some countries in the European Union have temporarily suspended use of the AstraZeneca COVID-19 vaccine as a precautionary measure based on reports of rare blood coagulation disorders in persons who had received the vaccine.
EMA clears use of COVID-19 Vaccine AstraZeneca europeanpharmaceuticalreview
March 22, 2021
The EMA’s drug safety committee concluded that the vaccine is not associated with an increased risk of thromboembolic events and that its benefits still outweigh its risks.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page